Research and Markets: in 2015 the Sales for Avastins Are Forecasted to Reach $1285M, Overshadowing Tarceva ($737m) and Erbitux ($696m).DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c35610) has announced the addition of Non-Small Cell Lung Cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. - Avastin to Lead the Market to their offering. Non-small cell lung cancer comprises over 75% of all lung cancers lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor tumor: see neoplasm. type and despite two decades of extensive R&D and chemotherapy use, the overall survival of NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there patients remains below 12 months. Scope of this title: Overview of NSCLC and the current treatment options, including profiles and analysis of existing drugs Insightful analysis of clinical trial data for late-phase drugs in development for NSCLC Future global sales of key pipeline drugs for NSCLC to 2015, including their clinical/research and commercial attractiveness Assessment of the clinical and commercial potential of the drugs currently in development for NSCLC Highlights of this title: Amgens pantitumumab will prove popular among physicians due to its favorable toxicity profile and EGFR EGFR Epidermal Growth Factor Receptor (a kinase enzyme) EGFR Estimated Glomerular Filtration Rate target. With pantitumumab seeking to gain initial approval in the first-line setting, it is believed the agent will rapidly gain ground on BMS/Merck KgGAs Erbitux, despite the latters first-to-market advantage. Over the forecast period to 2015, it is believed Avastin will be the sole MTT MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide MTT Machine Tool Technology MTT Microwave Theory and Techniques MTT Mobile Task Team MTT Multi-Table Tournament (poker) to achieve blockbuster status within the NSCLC market. Avastins 2015 sales of $1285m are forecast to eclipse those of Tarceva ($737m) and Erbitux ($696m). This is largely attributed to the size of Avastins target population within the first-line setting. In attempting to avoid the fate of AstraZenecas recently withdrawn drug Iressa, developers must allow for adequate maturation maturation /mat·u·ra·tion/ (mach-u-ra´shun) 1. the process of becoming mature. 2. attainment of emotional and intellectual maturity. 3. of trial data in order to explicitly demonstrate the clinical benefit of novel pipeline agents. The time/cost ratio of clinical development must be regularly reviewed to ensure the commercial success of innovative agents. Reasons to order your copy: Assess opportunities and risks in the NSCLC market by analyzing the clinical and commercial attractiveness of key agents Evaluate the potential of your product in the NSCLC cancer market by examining key pipeline drugs sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. Determine the commercial impact of new molecular-targeted agents entering the NSCLC market and their effects on the current treatment paradigms Source: Datamonitor For more information visit http://www.researchandmarkets.com/reports/c35610 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion